Mizuho Securities analyst Vamil Divan ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

Pfizer's (PFE) COVID Pill Best in Class, Will Put Pressure on Merck (MRK) and Regeneron (REGN) - AnalystNovember 5, 2021 8:47 AM Pfizer (PFE) Shares Surge 13% Following Game-Changing COVID-19 Pill Data, Merck (MRK) Down 9%; Analyst Sees Oral Antiviral Market Totaling 'Tens of Billion of Dollars Annually'November 5, 2021 8:23 AM Pfizer's (PFE) COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR StudyNovember 5, 2021 6:45 AM